Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro.

@article{Zhang2003InteractionOB,
  title={Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro.},
  author={Wenjian Zhang and Yamini Ramamoorthy and Rachel F. Tyndale and Edward Sellers},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  year={2003},
  volume={31 6},
  pages={
          768-72
        }
}
Buprenorphine is a thebaine derivative used in the treatment of heroin and other opiate addictions. In this study, the selective probe reactions for each of the major hepatic cytochromes P450 (P450s) were used to evaluate the effect of buprenorphine and its main metabolite norbuprenorphine on the activity of these P450s. The index reactions used were CYP1A2 (phenacetin O-deethylation), CYP2A6 (coumarin 7-hydroxylation), CYP2C9 (diclofenac 4'-hydroxylation), CYP2C19 (omeprazole 5-hydrxoylation… Expand
Effect of psychotropic medication on the in vitro metabolism of buprenorphine in human cDNA-expressed cytochrome P450 enzymes
TLDR
Both midazolam and zolpidem showed a distinct inhibitory potency towards NBUP formation by CYP 3A4, implicating a decreased conversion of BUP when preincubated, which strongly suggests a metabolically activated component in inhibition. Expand
Effect of nonspecific binding to microsomes and metabolic elimination of buprenorphine on the inhibition of cytochrome P4502D6.
TLDR
It is concluded that nonspecific binding to microsomes of the inhibitor could affect the inhibitory potency against CYP2D6 and a more precise estimate of the risk of adverse drug interaction could be achieved. Expand
Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.
TLDR
As the degree of opioid analgesia is largely dependent on M1 formation, methadone maintenance patients may not receive adequate analgesia from oral tramadol, and alternative analgesics whose metabolism is independent of CYP2D6 should be utilized in this patient population. Expand
Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation.
TLDR
The data clearly show that norbuprenorphine alone causes important deleterious effects on ventilation in rats, and buprenorphin protective effect calls into question the role for norb uprenorphines in respiratory toxicity associated with bup Renorphine use. Expand
Basic pharmacology of buprenorphine
TLDR
Buprenorphine is a safe and highly effective analgesic opioid for the treatment of chronic pain and in the study of the respiratory effects after intravenous infusion in rats, norbupenorphine was ten times more potent than the parent drug. Expand
Dexamethasone hepatic induction in rats subsequently treated with high dose buprenorphine does not lead to respiratory depression.
TLDR
The results suggest a limited role of drug-mediated CYP3A induction in the occurrence of buprenorphine-attributed respiratory depression in addicts and dexamethasone did not modify the effects of 30 mg kg(-1) bupenorphine on rat ventilation. Expand
Quantitative Prediction of Cytochrome P450 (CYP) 2D6-Mediated Drug Interactions
TLDR
Predictive distributions for 615 possible interactions were obtained, giving detailed information on some drugs or inhibitors that have been poorly studied so far, such as metoclopramide, bupropion and terbinafine. Expand
Methadone: a review of drug-drug and pathophysiological interactions
TLDR
This work set out to describe drug-drug interactions as well as physiological and pathophysiological factors that may impact the pharmacokinetics of methadone, and conducted a systematic search for papers and related abstracts published between 1966 and 2010. Expand
Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals.
TLDR
Findings suggest the potential for opioid toxicity among HCV-infected patients treated with buprenorphine/naloxone, and possible hepatotoxic effects related to increased bup Renorphine exposure. Expand
A Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions of Buprenorphine After Subcutaneous Administration of CAM2038 With Perpetrators of CYP3A4.
TLDR
The results provided insight into the potential DDI effect for CAM2038 and suggested a lack of clinically meaningful DDI when CAM 2038 is coadministered with CYP3A4 inhibitor or inducer. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
Inhibition of human drug metabolizing cytochrome P450 by buprenorphine.
TLDR
The effects of buprenorphine, a powerful mixed agonist/antagonist analgesic, on several cytochrome P450 isoform specific reactions in human liver microsomes were investigated and would not be predicted to cause clinically significant interactions with other CYP-metabolized drugs. Expand
Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.
TLDR
Tranylcypromine [particularly R-(+) isomer], tryptamine, and methoxsalen are specific and relatively selective for CYP2A6 and may be useful in vivo to decrease smoking by inhibiting nicotine metabolism with a low risk of metabolic drug interactions. Expand
Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4.
TLDR
The demonstration of BN N-dealkylation by recombinant CYP3A4 and the agreement in the affinities (apparent KM values) of human liver microsomes and recombinant cytochrome P450 enzyme(s) provide the most supportive evidence for BNN-dealksylation being catalyzed by CYP 3A4. Expand
Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes.
TLDR
Data demonstrate that P450 3A4 is the major enzyme involved in hepatic buprenorphine N-dealkylation, which is a long acting analgesic of the opiate family. Expand
Inhibition by fluoxetine of cytochrome P450 2D6 activity
TLDR
Inhibition of CYP2D6 activity in patients undergoing treatment with fluoxetine or other serotonin uptake inhibitors could contribute to toxicity or attenuated response from concurrent medications that are substrates of this enzyme. Expand
Designer Drugs That Are Potent Inhibitors of CYP2D6
TLDR
Conurrent oral use of CYP2D6 substrates with MPPP and PEPAP may represent a kinetic drug interaction risk, but this risk must be confirmed clinically. Expand
Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450
  • Y. Sai, R. Dai, +4 authors M. Shou
  • Chemistry, Medicine
  • Xenobiotica; the fate of foreign compounds in biological systems
  • 2000
TLDR
The results indicate that sulphaphenazole, quinidine and α-naphthoflavone are selective inhibitors of CYP2C9, CyP2D6 and CYP1A isoforms on the basis of the IC50, which are much lower than those of other P450 isoforms (> 10-fold). Expand
Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
TLDR
It is evident that CYP inhibitors do not exhibit the same selectivity in human and rat liver microsomes, due to differential selectivity of the inhibitors and/or differences in the CYP isoform responsible for metabolism in the different species. Expand
Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes.
TLDR
This study indicates orphenadrine cannot be used as a selective inhibitor of CYP2B6 in human liver microsomes and that methimazole is not a selective inhibitors of the flavin-containing monooxygenase in human Liver P450 enzyme activities. Expand
Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.
TLDR
Investigation of human liver microsomes for cytochrome P450 isoform-dependent reactions found alpha-Naphthoflavone and furafylline both inhibited phenacetin and 7-ethoxyresorufin O-deethylation processes, a consequence of the absence of CYP1A1 in noninduced human liver. Expand
...
1
2
3
4
...